Brief Summary
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 in participants with advancedat a late stage, far along hepatocellular carcinomacancer arising from tissues that line organs expressing GPC3.
Intervention / Treatment
- Drug: MT-303
Inclusion Criteria
- Aged 18 years or older
- Histological diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of advanced/recurrent or metastatic and/or unresectable HCC. [Note: participants with other tumor types expressing GPC3 may be eligible pending a discussion with the Medical Monitor]
- Measurable lesion per RECIST 1.1 criteria
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status gradea description of how abnormal cancer cells and tissue look under a microscope when compared to healthy cells of 0 or 1
- Child-Pugh score: Class A
- Adequate organ function